Tomohiko Aihara

Mino, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Optimizing axillary surgery for patients with clinically node-negative and node-positive breast cancer.

Optimizing axillary surgery for patients with clinically node-negative and node-positive breast cancer.

Journal: Surgery today

Published: March 31, 2026

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: February 12, 2026

Cosmetic outcomes of rotation flap and suture scaffold for breast-conserving therapy in the lower quadrants.

Cosmetic outcomes of rotation flap and suture scaffold for breast-conserving therapy in the lower quadrants.

Journal: Breast cancer (Tokyo, Japan)

Published: July 23, 2025

Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.

Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.

Journal: Breast cancer (Tokyo, Japan)

Published: February 03, 2025

A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy.

A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy.

Journal: Breast cancer (Tokyo, Japan)

Published: November 07, 2024

Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).

Journal: Breast cancer (Tokyo, Japan)

Published: July 04, 2024

Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.

Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.

Journal: EClinicalMedicine

Published: March 03, 2024

Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.

Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.

Journal: Acta medica Okayama

Published: December 22, 2022

Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.

Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.

Journal: Breast cancer research and treatment

Published: July 28, 2022

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.

Journal: World journal of oncology

Published: June 21, 2022

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.

Journal: PloS one

Published: May 26, 2022

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: September 25, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026